Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Tissue Engineering & Bioprinting: Research to Commercialization

Adam Hacking's Biography



Adam Hacking, Chief Scientific Officer, Oxford Performance Materials (OPM)

Dr. Hacking is the Chief Scientific Officer at Oxford Performance Materials (OPM). OPM provides high performance additive manufacturing (HPAM) solutions for the medical, aerospace & defense and industrial sectors. HPAM is enabling the development of a new generation of medical devices with functionality beyond patient specific fit. Prior to joining OPM, Dr. Hacking was director of the Laboratory for Musculoskeletal Research and Innovation in the Department of Orthopaedics at the Massachusetts General Hospital and a faculty member at Harvard Medical School. Dr. Hacking received his PhD in Biomedical Engineering from McGill University in 2006 where his work focused on implant fixation and biomaterials. Dr. Hacking completed two post doctoral fellowships, the first in the Department of Orthopaedics (Trauma and Fracture healing) at McGill University and the second at the Harvard-MIT Division of Health Sciences and Technology (Biomaterials / Tissue Engineering). Outside academia Dr. Hacking has founded 4 companies, 3 of which specialize in medical technology.

Adam Hacking Image

High Performance Additive Manufacturing for Long-Term Implantable Devices

Tuesday, 10 February 2015 at 08:30

Add to Calendar ▼2015-02-09 17:30:002015-02-09 18:30:00Europe/LondonHigh Performance Additive Manufacturing for Long-Term Implantable DevicesTissue Engineering and Bioprinting: Research to Commercialization in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

High performance additive manufacturing (HPAM) describes the direct fabrication of fully functional, mission critical devices. HPAM of medical devices requires an understanding of material properties, manufacturing techniques, device design and biological performance. Oxford performance materials has developed a unique laser sintering process with a high performance thermoplastic, poly-ether-ketone-ketone (PEKK) that enables the generation of load-bearing additively manufactured devices. OPM is the first company to have obtained FDA clearance for additively manufactured polymeric devices for long-term implantation. This talk will introduce OPM's technology, describe the development and commercialization process, provide an overview of the biological response to PEKK devices and outline current development.


Add to Calendar ▼2015-02-09 00:00:002015-02-10 00:00:00Europe/LondonTissue Engineering and Bioprinting: Research to CommercializationTissue Engineering and Bioprinting: Research to Commercialization in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com